Brief: U.S. FDA Grants Cumberland Pharmaceuticals Barrier-To-Innovation Waiver With Reditrex Product Line

Cumberland Pharmaceuticals

07/06/2023 22:21

June 7 (Reuters) - Cumberland Pharmaceuticals Inc
 CPIX.O :
    * CUMBERLAND PHARMACEUTICALS- ON JUNE 2 U.S. FDA INFORMED CO
THAT
IT HAD GRANTED A BARRIER-TO-INNOVATION WAIVER ASSOCIATED WITH
REDITREX PRODUCT LINE
    * CUMBERLAND PHARMACEUTICALS- WAIVER TO RESULT IN REFUND OF
ABOUT
$1.2 MILLION CO PAID FOR PRESCRIPTION DRUG PROGRAM FEES FOR
REDITREX PRODUCT LINE

Further company coverage:  CPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))